#BEGIN_DRUGCARD DB00551

# AHFS_Codes:
Not Available

# ATC_Codes:
G04BX03

# Absorption:
Well absorbed from the GI tract following oral administration.

# Biotransformation:
35-65% of oral dose excreted unchanged in urine (which provides the drug's therapeutic effect).

# Brand_Mixtures:
Not Available

# Brand_Names:
Lithostat

# CAS_Registry_Number:
546-88-3

# ChEBI_ID:
27777

# Chemical_Formula:
C2H5NO2

# Chemical_IUPAC_Name:
N-hydroxyacetamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Enzyme Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.59

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Acetohydroxamic Acid

# HET_ID:
HAE

# Half_Life:
5-10 hours in patients with normal renal function

# InChI_Identifier:
InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)

# InChI_Key:
InChIKey=RRUDCFGSUDOHDG-UHFFFAOYSA-N

# Indication:
Used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.

# KEGG_Compound_ID:
C06808

# KEGG_Drug_ID:
D00220

# LIMS_Drug_ID:
551

# Mechanism_Of_Action:
Acetohydroxamic Acid reversibly inhibits the bacterial enzyme urease. This inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms, leading to a decrease in pH and ammonia levels. As antimicrobial agents are more effective in such conditions, the effectiveness of these agents is amplified, resulting in a higher cure rate.

# Melting_Point:
90.5 °C

# Molecular_Weight_Avg:
75.0666

# Molecular_Weight_Mono:
75.032028409

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1Y93

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164749213

# Pharmacology:
Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.

# Predicted_LogP_Hydrophobicity:
-1.5

# Predicted_LogS:
0.83

# Predicted_Water_Solubility:
5.09e+02 g/l

# Primary_Accession_No:
DB00551

# Protein_Binding:
No known binding

# PubChem_Compound_ID:
1990

# PubChem_Substance_ID:
46508546

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00774
EXPT01688

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)NO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
AHA
Acethydroxamsaure
Acetic acid, oxime
Acetohydroxamate
Acetohydroximic acid
Acetyl hydroxyamino
Acetylhydroxamic acid
Cetohyroxamic acid
Methylhydroxamic acid
N-Hydroxyacetamide

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, rat: LD<sub>50</sub> = 4.8gm/kg. Symptoms of overdose include anorexia, malaise, lethargy, diminished sense of wellbeing, tremor, anxiety, nausea, and vomiting.

# Update_Date:
2013-02-08 16:19:26 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Acetohydroxamic_acid

# pKa_Isoelectric_Point:
8.7 (at 25 °C)

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11101668	Palinska KA, Jahns T, Rippka R, Tandeau De Marsac N: Prochlorococcus marinus strain PCC 9511, a picoplanktonic cyanobacterium, synthesizes the smallest urease. Microbiology. 2000 Dec;146 Pt 12:3099-107.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M36068

# Drug_Target_1_GenBank_ID_Protein:
149337

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ureC

# Drug_Target_1_Gene_Sequence:
>1704 bp
ATGAGTAATATTTCACGCCAGGCCTATGCCGATATGTTCGGCCCCACCGTCGGCGACAAG
GTGCGCCTGGCAGATACCGAGCTGTGGATCGAGGTGGAGGACGATTTGACCACCTACGGG
GAAGAGGTCAAATTCGGCGGCGGCAAAGTGATCCGCGACGGCATGGGCCAGGGACAGATG
CTGGCCGCCGACTGTGTCGACCTGGTGCTCACCAACGCGTTGATCGTCGATCACTGGGGG
ATCGTTAAGGCCGATATCGGCGTGAAGGACGGCCGGATCTTCGCCATCGGCAAAGCCGGC
AACCCCGACATCCAGCCCAACGTCACCATCCCCATCGGCGCTGCGACGGAAGTGATCGCC
GCCGAAGGAAAAATTGTCACCGCCGGCGGGATCGATACCCATATTCACTGGATCTGTCCG
CAGCAGGCGGAAGAGGCGCTGGTCTCTGGCGTGACCACCATGGTCGGCGGCGGCACCGGC
CCGGCCGCGGGCACCCATGCCACCACCTGCACCCCGGGCCCGTGGTATATCTCACGCATG
CTGCAGGCGGCCGACAGCCTGCCGGTCAATATCGGCCTGCTGGGCAAGGGAAACGTTTCT
CAGCCGGATGCCCTGCGCGAGCAGGTGGCGGCAGGCGTTATTGGCCTGAAGATCCATGAG
GACTGGGGCGCCACCCCGGCGGCGATCGACTGTGCGTTAACCGTCGCCGATGAAATGGAC
ATCCAGGTCGCCCTGCACAGCGACACCCTGAATGAATCCGGTTTTGTGGAAGACACCCTC
GCCGCCATCGGCGGGCGCACCATCCACACCTTCCATACCGAAGGGGCCGGCGGCGGCCAT
GCGCCGGACATCATCACCGCCTGCGCCCACCCGAACATTTTGCCGTCGTCCACCAACCCA
ACGCTGCCCTACACCCTCAACACCATCGATGAACATCTCGATATGCTGATGGTCTGCCAC
CATCTGGACCCGGACATCGCCGAGGACGTGGCCTTTGCCGAGTCGCGCATTCGCCGGGAA
ACCATCGCTGCGGAAGACGTGCTGCACGATCTCGGCGCCTTCTCGCTCACCTCCTCCGAT
TCGCAGGCCATGGGCCGCGTCGGGGAAGTGATTCTCCGCACCTGGCAGGTGGCGCATCGC
ATGAAGGTGCAGCGCGGAGCGCTGGCGGAGGAGACCGGGGATAACGACAACTTCCGCGTG
AAGCGCTACATCGCCAAATACACCATCAACCCGGCGCTGACCCACGGCATCGCACACGAA
GTCGGATCCATTGAGGTGGGTAAGCTGGCTGACCTCGTGGTCTGGTCACCAGCCTTCTTC
GGCGTGAAACCGGCCACCGTGATCAAAGGCGGCATGATCGCCATCGCGCCGATGGGCGAT
ATCAATGCCTCTATTCCGACCCCGCAGCCGGTGCACTACCGCCCGATGTTTGGCGCGCTG
GGCAGCGCCCGCCATCACTGCCGCCTCACCTTCCTGTCGCAGGCGGCGGCAGCCAATGGC
GTTGCCGAGCGGCTGAACCTGCGCAGCGCGATCGCCGTGGTGAAAGGCTGCCGTACGGTG
CAGAAAGCCGACATGGTGCACAACAGTCTGCAGCCTAACATCACCGTCGACGCCCAGACC
TATGAGGTGCGGGTGGATGGCGAACTTATCACCAGCGAGCCGGCAGACGTTCTGCCGATG
GCGCAACGATATTTTCTGTTTTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
10555581	Yamaguchi K, Cosper NJ, Stalhandske C, Scott RA, Pearson MA, Karplus PA, Hausinger RP: Characterization of metal-substituted Klebsiella aerogenes urease. J Biol Inorg Chem. 1999 Aug;4(4):468-77.
10913264	Pearson MA, Park IS, Schaller RA, Michel LO, Karplus PA, Hausinger RP: Kinetic and structural characterization of urease active site variants. Biochemistry. 2000 Jul 25;39(29):8575-84.
1624427	Lee MH, Mulrooney SB, Renner MJ, Markowicz Y, Hausinger RP: Klebsiella aerogenes urease gene cluster: sequence of ureD and demonstration that four accessory genes (ureD, ureE, ureF, and ureG) are involved in nickel metallocenter biosynthesis. J Bacteriol. 1992 Jul;174(13):4324-30.
2211515	Mulrooney SB, Hausinger RP: Sequence of the Klebsiella aerogenes urease genes and evidence for accessory proteins facilitating nickel incorporation. J Bacteriol. 1990 Oct;172(10):5837-43.
7754395	Jabri E, Carr MB, Hausinger RP, Karplus PA: The crystal structure of urease from Klebsiella aerogenes. Science. 1995 May 19;268(5213):998-1004.
8718850	Jabri E, Karplus PA: Structures of the Klebsiella aerogenes urease apoenzyme and two active-site mutants. Biochemistry. 1996 Aug 20;35(33):10616-26.
9558361	Pearson MA, Schaller RA, Michel LO, Karplus PA, Hausinger RP: Chemical rescue of Klebsiella aerogenes urease variants lacking the carbamylated-lysine nickel ligand. Biochemistry. 1998 Apr 28;37(17):6214-20.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
370

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
60305

# Drug_Target_1_Name:
Urease alpha subunit

# Drug_Target_1_Number_of_Residues:
567

# Drug_Target_1_PDB_ID:
2KAU

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00449	Urease_alpha
PF01979	Amidohydro_1

# Drug_Target_1_Protein_Sequence:
>Urease alpha subunit
MSNISRQAYADMFGPTVGDKVRLADTELWIEVEDDLTTYGEEVKFGGGKVIRDGMGQGQM
LAADCVDLVLTNALIVDHWGIVKADIGVKDGRIFAIGKAGNPDIQPNVTIPIGAATEVIA
AEGKIVTAGGIDTHIHWICPQQAEEALVSGVTTMVGGGTGPAAGTHATTCTPGPWYISRM
LQAADSLPVNIGLLGKGNVSQPDALREQVAAGVIGLKIHEDWGATPAAIDCALTVADEMD
IQVALHSDTLNESGFVEDTLAAIGGRTIHTFHTEGAGGGHAPDIITACAHPNILPSSTNP
TLPYTLNTIDEHLDMLMVCHHLDPDIAEDVAFAESRIRRETIAAEDVLHDLGAFSLTSSD
SQAMGRVGEVILRTWQVAHRMKVQRGALAEETGDNDNFRVKRYIAKYTINPALTHGIAHE
VGSIEVGKLADLVVWSPAFFGVKPATVIKGGMIAIAPMGDINASIPTPQPVHYRPMFGAL
GSARHHCRLTFLSQAAAANGVAERLNLRSAIAVVKGCRTVQKADMVHNSLQPNITVDAQT
YEVRVDGELITSEPADVLPMAQRYFLF

# Drug_Target_1_Reaction:
urea + H2O = CO2 + 2 NH3

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P18314

# Drug_Target_1_SwissProt_Name:
URE1_KLEAE

# Drug_Target_1_Synonyms:
EC 3.5.1.5
Urea amidohydrolase alpha subunit

# Drug_Target_1_Theoretical_pI:
5.03

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15809432	Bertini I, Calderone V, Cosenza M, Fragai M, Lee YM, Luchinat C, Mangani S, Terni B, Turano P: Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5334-9. Epub 2005 Apr 4.
16899369	Mannino C, Nievo M, Machetti F, Papakyriakou A, Calderone V, Fragai M, Guarna A: Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors. Bioorg Med Chem. 2006 Nov 15;14(22):7392-403. Epub 2006 Aug 8.
16959356	Fukuda M, Peppas NA, McGinity JW: Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J Control Release. 2006 Oct 10;115(2):121-9. Epub 2006 Jul 21.
17269766	Bertini I, Calderone V, Fragai M, Giachetti A, Loconte M, Luchinat C, Maletta M, Nativi C, Yeo KJ: Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases. J Am Chem Soc. 2007 Mar 7;129(9):2466-75. Epub 2007 Feb 2.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MMP12

# Drug_Target_2_GenBank_ID_Gene:
L23808

# Drug_Target_2_GenBank_ID_Protein:
435970

# Drug_Target_2_GeneCard_ID:
MMP12

# Drug_Target_2_Gene_Name:
MMP12

# Drug_Target_2_Gene_Sequence:
>1413 bp
ATGAAGTTTCTTCTAATACTGCTCCTGCAGGCCACTGCTTCTGGAGCTCTTCCCCTGAAC
AGCTCTACAAGCCTGGAAAAAAATAATGTGCTATTTGGTGAGAGATACTTAGAAAAATTT
TATGGCCTTGAGATAAACAAACTTCCAGTGACAAAAATGAAATATAGTGGAAACTTAATG
AAGGAAAAAATCCAAGAAATGCAGCACTTCTTGGGTCTGAAAGTGACCGGGCAACTGGAC
ACATCTACCCTGGAGATGATGCACGCACCTCGATGTGGAGTCCCCGATCTCCATCATTTC
AGGGAAATGCCAGGGGGGCCCGTATGGAGGAAACATTATATCACCTACAGAATCAATAAT
TACACACCTGACATGAACCGTGAGGATGTTGACTACGCAATCCGGAAAGCTTTCCAAGTA
TGGAGTAATGTTACCCCCTTGAAATTCAGCAAGATTAACACAGGCATGGCTGACATTTTG
GTGGTTTTTGCCCGTGGAGCTCATGGAGACTTCCATGCTTTTGATGGCAAAGGTGGAATC
CTAGCCCATGCTTTTGGACCTGGATCTGGCATTGGAGGGGATGCACATTTCGATGAGGAC
GAATTCTGGACTACACATTCAGGAGGCACAAACTTGTTCCTCACTGCTGTTCACGAGATT
GGCCATTCCTTAGGTCTTGGCCATTCTAGTGATCCAAAGGCTGTAATGTTCCCCACCTAC
AAATATGTCGACATCAACACATTTCGCCTCTCTGCTGATGACATACGTGGCATTCAGTCC
CTGTATGGAGACCCAAAAGAGAACCAACGCTTGCCAAATCCTGACAATTCAGAACCAGCT
CTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGTGGGAAATAAGATCTTTTTC
TTCAAAGACAGGTTCTTCTGGCTGAAGGTTTCTGAGAGACCAAAGACCAGTGTTAATTTA
ATTTCTTCCTTATGGCCAACCTTGCCATCTGGCATTGAAGCTGCTTATGAAATTGAAGCC
AGAAATCAAGTTTTTCTTTTTAAAGATGACAAATACTGGTTAATTAGCAATTTAAGACCA
GAGCCAAATTATCCCAAGAGCATACATTCTTTTGGTTTTCCTAACTTTGTGAAAAAAATT
GATGCAGCTGTTTTTAACCCACGTTTTTATAGGACCTACTTCTTTGTAGATAACCAGTAT
TGGAGGTATGATGAAAGGAGACAGATGATGGACCCTGGTTATCCCAAACTGATTACCAAG
AACTTCCAAGGAATCGGGCCTAAAATTGATGCAGTCTTCTATTCTAAAAACAAATACTAC
TATTTCTTCCAAGGATCTAACCAATTTGAATATGACTTCCTACTCCAACGTATCACCAAA
ACACTGAAAAGCAATAGCTGGTTTGGTTGTTAG

# Drug_Target_2_General_Function:
Involved in protease activity

# Drug_Target_2_General_References:
11575928	Lang R, Kocourek A, Braun M, Tschesche H, Huber R, Bode W, Maskos K: Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J Mol Biol. 2001 Sep 28;312(4):731-42.
11575929	Nar H, Werle K, Bauer MM, Dollinger H, Jung B: Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J Mol Biol. 2001 Sep 28;312(4):743-51.
8226919	Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993 Nov 15;268(32):23824-9.
9115292	Gronski TJ Jr, Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD: Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 1997 May 2;272(18):12189-94.

# Drug_Target_2_HGNC_ID:
HGNC:7158

# Drug_Target_2_HPRD_ID:
03027

# Drug_Target_2_ID:
2203

# Drug_Target_2_Locus:
11q22.3

# Drug_Target_2_Molecular_Weight:
54002

# Drug_Target_2_Name:
Macrophage metalloelastase

# Drug_Target_2_Number_of_Residues:
470

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_2_Protein_Sequence:
>Macrophage metalloelastase precursor
MKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYSGNLM
KEKIQEMQHFLGLKVTGQLDTSTLEMMHAPRCGVPDVHHFREMPGGPVWRKHYITYRINN
YTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDFHAFDGKGGI
LAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTY
KYVDINTFRLSADDIRGIQSLYGDPKENQRLPNPDNSEPALCDPNLSFDAVTTVGNKIFF
FKDRFFWLKVSERPKTSVNLISSLWPTLPSGIEAAYEIEARNQVFLFKDDKYWLISNLRP
EPNYPKSIHSFGFPNFVKKIDAAVFNPRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITK
NFQGIGPKIDAVFYSKNKYYYFFQGSNQFEYDFLLQRITKTLKSNSWFGC

# Drug_Target_2_Reaction:
Hydrolysis of soluble and insoluble elastin [1]. Specific cleavages are also produced at -Ala14!Leu- and -Tyr16!Leu- in the B chain of insulin [2]

# Drug_Target_2_Signals:
1-16

# Drug_Target_2_Specific_Function:
May be involved in tissue injury and remodeling. Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3

# Drug_Target_2_SwissProt_ID:
P39900

# Drug_Target_2_SwissProt_Name:
MMP12_HUMAN

# Drug_Target_2_Synonyms:
EC 3.4.24.65
HME
ME
MMP-12
Macrophage elastase
Macrophage metalloelastase precursor
Matrix metalloproteinase-12

# Drug_Target_2_Theoretical_pI:
8.98

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00551
